Maze Therapeutics Inc
MAZE45.030USD
+1.080+2.46%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
2.16BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Maze Therapeutics Inc Unternehmen
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Inc Informationen
BörsenkürzelMAZE
Name des UnternehmensMaze Therapeutics Inc
IPO-datumJan 31, 2025
CEOColoma (Jason V)
Anzahl der mitarbeiter125
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse171 Oyster Point Boulevard, Suite 300
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16508505070
Websitehttps://www.mazetx.com/
BörsenkürzelMAZE
IPO-datumJan 31, 2025
CEOColoma (Jason V)
Führungskräfte von Maze Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2024
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Andere
57.45%
Aktionäre
Aktionäre
Anteil
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Andere
57.45%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
35.70%
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
13.22%
Private Equity
10.76%
Investment Advisor
9.98%
Individual Investor
1.88%
Family Office
1.00%
Research Firm
0.45%
Endowment Fund
0.19%
Andere
10.36%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
154
41.80M
86.88%
+1.94M
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Third Rock Ventures, LLC
5.42M
11.27%
-1.60M
-22.78%
Nov 04, 2025
Frazier Life Sciences Management, L.P.
4.57M
9.49%
-1.00
-0.00%
Sep 30, 2025
ARCH Venture Partners
4.12M
8.56%
--
--
Sep 30, 2025
Deep Track Capital LP
3.95M
8.21%
--
--
Sep 30, 2025
Alphabet, Inc.
2.41M
5.01%
--
--
Sep 30, 2025
Andreessen Horowitz
1.70M
3.54%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.33M
2.77%
+915.34K
+218.14%
Sep 30, 2025
Matrix Capital Management Company, LP
1.65M
3.44%
-832.50K
-33.49%
Sep 30, 2025
VR Adviser, LLC
1.23M
2.56%
+1.23M
--
Sep 30, 2025
Logos Global Management LP
1.23M
2.55%
+615.39K
+100.57%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.53%
ALPS Medical Breakthroughs ETF
Anteil0.39%
iShares Micro-Cap ETF
Anteil0.12%
iShares Russell 2000 Value ETF
Anteil0.04%
ProShares UltraPro Russell2000
Anteil0.03%
ProShares Hedge Replication ETF
Anteil0.03%
iShares Russell 2000 ETF
Anteil0.02%
Proshares Ultra Russell 2000
Anteil0.02%
Schwab U.S. Small-Cap ETF
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
